In November last year, the US Food and Drug Administration approved a weight loss drug for the US market by the Indianapolis-based firm Eli Lilly, to rival the success of Novo Nordisk’s Wegovy.The drug, Zepbound, is a rebrand of Eli Lilly’s type 2 diabetes drug Mounjaro, which was already approved for use on the US […]